| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 580.39 | 2.3% | 10.9% |
| Total Income | 585.68 | 2.0% | 11.1% |
| Expenditure | 546.92 | 2.4% | 9.5% |
| PBT | 27.55 | 32.0% | 0.9% |
| Net Profit | 20.58 | 31.3% | 0.2% |
| OPM | 7.94% | 2.12pp | 7.83pp |
| NPM | 3.51% | 1.71pp | 0.38pp |
| EPS | 0.70 | 31.4% | 80.0% |
IOL Chemicals & Pharmaceuticals Reports Q3 & 9M FY26 Results: PBT Up 39% YoY, Margin Expansion
11 Feb 2026 · 11 Feb, 6:22 pm
Summary
IOL Chemicals & Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its Financial Results for the quarter and nine months ended 31st December 2025. The company reported a 39.3% YoY increase in PBT and a 10.9% YoY increase in revenue from operations in Q3 FY26. The Pharmaceuticals segment contributed 61% to the overall revenue, showing an 18% year-on-year growth.
Key Highlights
- 1
Revenue from Operations: 580.4 Cr (Q3FY26), 523.3 Cr (Q3FY25)
- 2
EBITDA: 62.6 Cr (Q3FY26), 50.9 Cr (Q3FY25)
- 3
PBT: 38.8 Cr (Q3FY26), 27.8 Cr (Q3FY25)
- 4
Pharmaceuticals segment revenue growth: 18% YoY
- 5
Pharmaceuticals segment contribution to overall revenue: 61% (Q3 FY26)
Management Comments
Mr Vikas Gupta
Joint Managing Director
Q3 FY26 has been a resilient quarter for IOL, marked by double-digit revenue growth, margin expansion, and a 39% YoY increase in profit before exceptional items and tax, despite prevailing geopolitical uncertainties. This performance underscores the resilience of our operations and sustained demand across our businesses.
Informational and educational content only. Not investment advice.